Medline has fallen almost 25% since his recommendation, which he largely blames on private-market holders selling while long-term investors buy publicly; he sees that as promising. At its current valuation, he expects 11-15% annual returns over five years from this well-managed medical-supplies giant.

The next company is Medline, another company that has gone public with a large private shareholder actively selling its stake in the public markets. For me, this is unlikely. So again, a second company is down almost 25% since I recommended it.

Medline , and its stock exchange symbol is MDLN. But again, in this case, private market shareholders are selling, while large and reliable long-term investors such as Fidelity, T.

Rowe Price, Baillie Gifford, and Invesco are buying shares in the public markets. This is a promising development for me in my assessment of the company.

Medline is a huge manufacturer and distributor of everyday medical supplies. That is, medical clothing, bandages and gloves, and it supplies them to hospitals, clinics and nursing homes.

It is essentially the infrastructure upon which healthcare services are based. It is a very well-managed company. This is a company with sales in the tens of billions of dollars.

This is a giant that has put its shares up for public subscription. It is currently working on moving beyond the stage of changing its ownership structure in public markets. I believe this is the main reason that led to the stock's decline.

And here, at its current valuation, I think you can get a good annual return of between 11 and 15% for this company over the next five years.